The Experts below are selected from a list of 42966 Experts worldwide ranked by ideXlab platform
Bee K Tan - One of the best experts on this subject based on the ideXlab platform.
-
decreased cerebrospinal fluid plasma ratio of the novel satiety molecule nesfatin 1 nucb 2 in obese humans evidence of nesfatin 1 nucb 2 resistance and implications for Obesity treatment
The Journal of Clinical Endocrinology and Metabolism, 2011Co-Authors: Bee K Tan, Manfred Hallschmid, Werner Kern, Hendrik Lehnert, Harpal S RandevaAbstract:Decreased cerebrospinal fluid/plasma ratio of nesfatin-1/NUCB-2 in Obesity is indicative of nesfatin-1/NUCB-2 resistance with implications for Obesity Management.
Yuting Wang - One of the best experts on this subject based on the ideXlab platform.
-
undaria pinnatifida improves Obesity related outcomes in association with gut microbiota and metabolomics modulation in high fat diet fed mice
Applied Microbiology and Biotechnology, 2020Co-Authors: Yuting Wang, Jingyi Yuan, Zhengyi Liu, Song QinAbstract:Dietary fiber has beneficial effects on Obesity-related diseases and gut microbiota, contributing a key role in the interaction between dietary metabolism and host metabolism. Our objective was to investigate the cause of the improvement in multiple types of physiological states with seaweed Undaria pinnatifida treatment on high-fat diet-fed mice and to evaluate whether its consequent anti-adiposity and anti-hyperlipidemic effects are associated with gut microbiota and its metabolomics regulation. U. pinnatifida administration in our experiment was shown to significantly decrease high-fat diet-induced body weight gain, as well as epididymal and abdominal adiposity. U. pinnatifida intake also significantly reduced liver weight and serum triacylglycerol accumulation. We also found that improving effects of U. pinnatifida on high-fat diet-induced metabolic dysfunctions were associated with significant increase in specific bacteria, such as Bacteroides acidifaciens and Bacteroides ovatus, as well as metabolites, including short-chain fatty acids and tricarboxylic acid cycle intermediates. Our result provides a cheap dietary strategy to host metabolism improvement and Obesity Management. KEY POINTS: • U. pinnatifida improved adipose accumulation and lipid metabolism. • B. acidifaciens and B. ovatus contributed to the beneficial effects of U. pinnatifida. • SCFAs and TCA cycle intermediates were critical to the metabolic outcomes. • Our study provides a cheap dietary strategy for Obesity Management.
Harpal S Randeva - One of the best experts on this subject based on the ideXlab platform.
-
decreased cerebrospinal fluid plasma ratio of the novel satiety molecule nesfatin 1 nucb 2 in obese humans evidence of nesfatin 1 nucb 2 resistance and implications for Obesity treatment
The Journal of Clinical Endocrinology and Metabolism, 2011Co-Authors: Bee K Tan, Manfred Hallschmid, Werner Kern, Hendrik Lehnert, Harpal S RandevaAbstract:Decreased cerebrospinal fluid/plasma ratio of nesfatin-1/NUCB-2 in Obesity is indicative of nesfatin-1/NUCB-2 resistance with implications for Obesity Management.
Christopher C Thompson - One of the best experts on this subject based on the ideXlab platform.
-
the role of endoscopic therapy in Obesity Management intragastric balloons and aspiration therapy
Diabetes Metabolic Syndrome and Obesity: Targets and Therapy, 2017Co-Authors: Nitin Kumar, Shelby Sullivan, Christopher C ThompsonAbstract:Weight Management is increasingly incorporating endoscopic bariatric therapy (EBT). As the global burden of Obesity and its comorbidities has increased, it is evident that novel therapeutic approaches will be necessary to address the Obesity epidemic. EBTs offer greater efficacy than diet and lifestyle modification and lower invasiveness than bariatric surgery. The US Food and Drug Administration has approved two intragastric balloons and aspiration therapy for the treatment of Obesity: Apollo Orbera is indicated for the treatment of Class I and Class II Obesity, Re Shape Integrated Dual Balloon system is indicated for the same range with a comorbidity, and Aspire Bariatrics AspireAssist is approved for patients with a body mass index of 35-55 kg/m2. These devices have proven safe and effective in clinical trials and are gaining commercial acceptance in the USA; the Orbera has been used extensively outside the USA for over 20 years. These devices will need to be delivered in the context of a multidisciplinary weight loss program, integrating comprehensive care of Obesity. Patient selection is important, and ensuring appropriate patient expectations and understanding of alternatives such as pharmacologic therapy and surgery is essential. With several EBTs on the horizon, patients with Obesity will have an even broader array of safe and effective options for weight Management in the future.
-
the influence of the orbera intragastric balloon filling volumes on weight loss tolerability and adverse events a systematic review and meta analysis
Obesity Surgery, 2017Co-Authors: Nitin Kumar, Christopher C Thompson, Fateh Bazerbachi, Tarun Rustagi, Thomas R Mccarty, Manoel Galvao Neto, Natan Zundel, Erik B Wilson, Christopher J Gostout, Barham Abu K DayyehAbstract:Background The Orbera intragastric balloon (IGB) has been approved by the US Food and Drug Administration for use in patients with a body mass index (BMI) between 30 and 40 kg/m2 and is in wide use worldwide as a primary and bridge Obesity Management tool. The balloon filling volume (BFV) ranges between 400 and 700 mL of saline. Our objective was to determine whether there is an association between BFV and clinically relevant endpoints, namely weight loss outcomes, balloon tolerability, and adverse events.
Song Qin - One of the best experts on this subject based on the ideXlab platform.
-
undaria pinnatifida improves Obesity related outcomes in association with gut microbiota and metabolomics modulation in high fat diet fed mice
Applied Microbiology and Biotechnology, 2020Co-Authors: Yuting Wang, Jingyi Yuan, Zhengyi Liu, Song QinAbstract:Dietary fiber has beneficial effects on Obesity-related diseases and gut microbiota, contributing a key role in the interaction between dietary metabolism and host metabolism. Our objective was to investigate the cause of the improvement in multiple types of physiological states with seaweed Undaria pinnatifida treatment on high-fat diet-fed mice and to evaluate whether its consequent anti-adiposity and anti-hyperlipidemic effects are associated with gut microbiota and its metabolomics regulation. U. pinnatifida administration in our experiment was shown to significantly decrease high-fat diet-induced body weight gain, as well as epididymal and abdominal adiposity. U. pinnatifida intake also significantly reduced liver weight and serum triacylglycerol accumulation. We also found that improving effects of U. pinnatifida on high-fat diet-induced metabolic dysfunctions were associated with significant increase in specific bacteria, such as Bacteroides acidifaciens and Bacteroides ovatus, as well as metabolites, including short-chain fatty acids and tricarboxylic acid cycle intermediates. Our result provides a cheap dietary strategy to host metabolism improvement and Obesity Management. KEY POINTS: • U. pinnatifida improved adipose accumulation and lipid metabolism. • B. acidifaciens and B. ovatus contributed to the beneficial effects of U. pinnatifida. • SCFAs and TCA cycle intermediates were critical to the metabolic outcomes. • Our study provides a cheap dietary strategy for Obesity Management.
